Safety Halts Reata's CKD Trial of Abbott-Partnered AIM Drug
Reata Pharmaceuticals Inc. ended a Phase III trial testing bardoxolone methyl in patients with Stage IV chronic kidney disease (CKD) and Type II diabetes after the independent data monitoring committee (IDMC) pointed to safety signals in the treatment arm, halting development of a drug that had once been hailed a potential blockbuster.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter